Mechanism of SSRI
1. 5HT1A centrally • Relief of depression • Anxiolytic effect 2. 5HT2A in spinal cord • Sexual dysfunction: delayed ejaculation, anorgasmia, decreased interest/libido 3. 5HT2C/5HT2A in brain • Activation: anxiety, insomnia • Worst with fluoxetine, paroxetine • Warn patients anxiety may worsen in first 1-2 wk of treatment 4. 5HT3A in gut • GI upset: nausea, vomiting, bloating • Take with food
Treatment strategies for refractory depression
Pharmacological approach, changing drugs
First line and second line
2. TCA, mianserin, MAOI
Side effects
Most sedating->option if insomnia
Mirtazepine, take at night
Also fewer sexual dysfunction
Avoid in liver impairment
Duloxetine
Avoid in evening because of insomnia
Fluoxetine
Moclobemide
Initial weight loss
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
++Orthostatic hypotension
Fluoxetine Paroxetine Sertraline SNRIs Moclobemide
Risks of hyponatremia
Risk factors for hyponatraemia include:
older age
female gender
low body weight
concurrent drugs (eg diuretics, NSAIDs, carbamazepine, chemotherapy)
impaired renal function
comorbidity (eg hypothyroidism, diabetes, chronic obstructive pulmonary disease, hypertension, stroke, head injury)
hot weather.
First line treatment option for depression with psychosis
Counselling a patient on antidepressants